Diamicron

How to order Diamicron

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Diamicron on Prescriptsy

Diamicron is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Diamicron is the brand name for gliclazide modified-release tablets, a sulphonylurea medicine used to lower blood glucose in adults with type 2 diabetes mellitus.

It is prescribed when lifestyle measures, including diet, regular physical activity, and weight management, have not achieved adequate blood glucose control.

Diamicron MR provides the convenience of once-daily dosing and is one of the most widely prescribed sulphonylureas in the United Kingdom, valued for its well-established efficacy, favourable safety profile within the sulphonylurea class, and demonstrated cardiovascular safety in the landmark ADVANCE trial.

Type 2 diabetes affects approximately 4.3 million people in the UK and is a major cause of cardiovascular disease, kidney disease, visual impairment, lower limb amputation, and reduced life expectancy.

Effective blood glucose control reduces the risk of these complications. While metformin is the recommended first-line pharmacological treatment, many patients require additional glucose-lowering therapy as the condition progresses.

Gliclazide is one of the most commonly used second-line agents, either alongside metformin or, where metformin is not tolerated or contraindicated, as a first-line alternative.

This page provides a comprehensive clinical overview of Diamicron, covering how it works, correct dosing, monitoring, side effects, safety warnings, and how to obtain a prescription in the UK.

Important safety information about Diamicron

Before reading further, note the following essential safety points. Diamicron is a prescription-only medicine (POM) and must be used under medical supervision.

• Gliclazide can cause hypoglycaemia (low blood sugar), which can be dangerous. Learn to recognise the symptoms (sweating, shaking, hunger, confusion) and always carry rapid-acting glucose.
• Do not skip or delay meals while taking Diamicron.
• Inform the DVLA if you experience a hypoglycaemic episode requiring assistance from another person. Check blood glucose before driving.
• Do not take Diamicron if you have type 1 diabetes, diabetic ketoacidosis, severe liver disease, or if you are pregnant or breastfeeding.
• Seek emergency medical help (call 999 or attend A&E) if you experience a severe hypoglycaemic episode with loss of consciousness or seizure.

Understanding type 2 diabetes

Type 2 diabetes is a chronic metabolic condition characterised by insulin resistance (where the body's cells do not respond effectively to insulin) and progressive decline in pancreatic beta cell function (leading to insufficient insulin production).

The result is sustained elevation of blood glucose, which over years causes damage to blood vessels and nerves throughout the body.

Risk factors include excess body weight (particularly central adiposity), physical inactivity, family history, South Asian, Black African, or Afro-Caribbean ethnic background, and increasing age.

In the UK, approximately 90% of all diabetes diagnoses are type 2.

Many people with type 2 diabetes also have associated conditions including hypertension, dyslipidaemia, and non-alcoholic fatty liver disease, collectively increasing cardiovascular risk.

NICE guideline NG28 recommends a stepwise approach to glucose-lowering therapy, beginning with lifestyle modification and metformin, and adding further agents as needed to achieve individualised HbA1c targets. Gliclazide is positioned as a key option at each escalation step.

How Diamicron works: mechanism of action

Gliclazide belongs to the sulphonylurea class of oral hypoglycaemic agents. Its primary mechanism is stimulation of insulin secretion from pancreatic beta cells.

It binds with high affinity to the sulphonylurea receptor 1 (SUR1) subunit of the ATP-sensitive potassium channel on the beta cell membrane.

This binding causes the channel to close, preventing potassium efflux and resulting in membrane depolarisation.

The depolarisation opens voltage-gated calcium channels, allowing calcium to enter the cell and trigger exocytosis of insulin-containing granules.

Gliclazide also has extrapancreatic effects. It enhances peripheral insulin sensitivity, improving glucose uptake by skeletal muscle and adipose tissue.

Additionally, it possesses antioxidant properties, reducing oxidative stress on vascular endothelium, which may contribute to the favourable cardiovascular profile observed in clinical trials.

The modified-release formulation of Diamicron uses a hydrophilic matrix system that releases gliclazide gradually over the course of the day, providing a plasma concentration profile that aligns with meal-related glycaemic excursions and reduces the risk of hypoglycaemia compared with standard-release gliclazide given at equivalent effective doses.

Clinical evidence and NICE positioning

The ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) trial was a landmark randomised controlled trial involving over 11,000 patients with type 2 diabetes across 20 countries.

The intensive glucose-lowering arm, which used gliclazide MR as the mandatory first-line agent, achieved a median HbA1c of 48 mmol/mol (6.5%) and demonstrated a significant 10% reduction in the combined outcome of major macrovascular and microvascular events, driven primarily by a 21% reduction in nephropathy.

Importantly, the rates of severe hypoglycaemia and cardiovascular mortality were low, providing reassurance about the safety of gliclazide MR-based intensive therapy.

NICE guideline NG28 positions a sulphonylurea (with gliclazide as the preferred option within the class) as a suitable addition to metformin when HbA1c rises above the individualised target.

It may also be used as first-line monotherapy when metformin is contraindicated or not tolerated.

NICE acknowledges that other second-line options, including DPP-4 inhibitors, SGLT2 inhibitors, pioglitazone, and GLP-1 receptor agonists, may be preferred in specific clinical scenarios, but gliclazide remains a cost-effective and evidence-based choice.

Dosage and administration

Diamicron MR 30 mg tablets are the most commonly prescribed formulation. Take the tablet(s) once daily with breakfast, swallowed whole with water. Do not crush, chew, or split the modified-release tablets, as this disrupts the slow-release mechanism.

The usual starting dose is 30 mg once daily.

If blood glucose control remains inadequate after at least 4 weeks, the dose may be increased in 30 mg increments up to a maximum of 120 mg daily (four 30 mg tablets taken together).

All tablets should be taken as a single dose with the morning meal.

Standard-release gliclazide 80 mg tablets are also available.

The starting dose is typically 40 mg (half a tablet) to 80 mg daily, taken with meals, and may be increased to a maximum of 320 mg daily in divided doses.

When switching from standard-release to MR formulation, 30 mg MR is considered approximately equivalent to 80 mg standard-release. The two formulations must not be mixed.

Blood glucose and HbA1c should be monitored regularly.

The target HbA1c depends on individual circumstances: NICE recommends 48 mmol/mol (6.5%) for patients on monotherapy and 53 mmol/mol (7.0%) for those on dual therapy including a sulphonylurea, though higher targets may be appropriate for older or frail patients to reduce hypoglycaemia risk.

Side effects of Diamicron

Hypoglycaemia

The most significant adverse effect is hypoglycaemia.

Symptoms include sweating, tremor, hunger, pallor, palpitations, dizziness, difficulty concentrating, confusion, irritability, visual disturbance, and in severe cases loss of consciousness or seizures.

Hypoglycaemia is more likely if meals are missed or delayed, during excessive exercise, after alcohol consumption, in renal or hepatic impairment, in elderly patients, and when gliclazide is combined with other glucose-lowering medicines.

All patients should be educated on recognising and self-treating mild hypoglycaemia with fast-acting carbohydrate (15 to 20 g of glucose tablets, a sugary drink, or fruit juice), followed by a longer-acting carbohydrate snack.

Severe hypoglycaemia (requiring assistance from another person or resulting in loss of consciousness) is a medical emergency; call 999 immediately.

Other common side effects

Gastrointestinal symptoms including nausea, diarrhoea, constipation, and abdominal pain occur in some patients, usually early in treatment and typically resolving with continued use.

Weight gain is a recognised class effect of sulphonylureas, driven by the insulin-stimulating mechanism; average weight gain is typically 1 to 3 kg over the first year.

Uncommon and rare side effects

Skin reactions (rash, itching, urticaria), elevated liver enzymes, cholestatic jaundice, hepatitis, and blood dyscrasias (thrombocytopenia, leucopenia, agranulocytosis, haemolytic anaemia) are rare.

Very rare severe hypersensitivity reactions including Stevens-Johnson syndrome and vasculitis have been reported. Hyponatraemia has been documented on rare occasions.

When to seek medical advice

Seek emergency care (call 999 or attend A&E) for severe hypoglycaemia with loss of consciousness, seizure, or inability to swallow, or for a widespread blistering skin rash.

Contact your GP or NHS 111 for persistent gastrointestinal symptoms, unexplained bruising or bleeding, jaundice, or any new symptoms that concern you.

Report any suspected adverse reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Contraindications

Diamicron must not be used in type 1 diabetes, diabetic ketoacidosis, diabetic pre-coma or coma, severe renal impairment (where insulin is preferred), severe hepatic impairment, pregnancy, breastfeeding, or in patients with known hypersensitivity to gliclazide, other sulphonylureas, or sulphonamides.

Driving

Patients taking gliclazide must be aware of the risk of hypoglycaemia while driving.

DVLA guidance requires that you check blood glucose before driving and at regular intervals (every 2 hours) during long journeys.

Do not drive if your blood glucose is below 5 mmol/L.

If you experience a hypoglycaemic episode requiring help from another person, you must inform the DVLA and may face temporary licence restrictions.

Drug interactions

Several medicines can increase the hypoglycaemic effect of gliclazide, including azole antifungals (miconazole, fluconazole), fibrates, MAO inhibitors, sulphonamide antibiotics, clarithromycin, and ACE inhibitors at high doses.

Corticosteroids, thiazide diuretics, and oral contraceptives may raise blood glucose and reduce gliclazide's effectiveness. Concurrent use with other glucose-lowering agents requires careful dose titration and monitoring.

Intercurrent illness

During acute illness (infection, surgery, trauma), glycaemic control may deteriorate significantly.

Patients should follow sick-day rules: continue monitoring blood glucose frequently, maintain hydration, do not stop diabetes medication unless advised by a healthcare professional, and contact your GP or diabetes team promptly if blood glucose becomes persistently high or if you develop vomiting or dehydration.

Temporary insulin therapy may be required.

How to get a Diamicron prescription in the UK

Diamicron is a prescription-only medicine. Your GP, practice nurse prescriber, or diabetes specialist can prescribe it as part of a structured type 2 diabetes management plan.

Regular monitoring, including HbA1c testing every 3 to 6 months and annual diabetes reviews (including kidney function, foot examination, retinal screening, and cardiovascular risk assessment), should continue throughout treatment.

The standard NHS prescription charge in England is currently 9.90 pounds per item.

However, patients with diabetes in England are entitled to free prescriptions by applying for a medical exemption certificate (form FP92A, available from your GP surgery).

Prescriptions are free for all patients in Scotland, Wales, and Northern Ireland.

Authorised online prescribers registered with the General Pharmaceutical Council (GPhC) may also prescribe gliclazide following a suitable clinical assessment.

When to seek further medical advice

Contact your GP, practice nurse, or diabetes team if you are experiencing frequent hypoglycaemic episodes, if your HbA1c is not reaching target despite taking the maximum dose, or if you develop new symptoms during treatment.

Seek emergency care (call 999 or attend A&E) for severe hypoglycaemia, diabetic ketoacidosis symptoms (persistent vomiting, abdominal pain, rapid breathing, fruity breath odour), or a severe allergic reaction.

Report suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Sources

• Diamicron MR 30 mg, Summary of Product Characteristics (EMC)
• Gliclazide, British National Formulary (BNF)
• NICE NG28: Type 2 diabetes in adults, management
• NICE CKS: Diabetes, type 2
• Type 2 diabetes, NHS
• Diabetes and driving, GOV.UK (DVLA)
• MHRA Yellow Card Scheme